AGN:NYE-Allergan plc (USD)

COMMON STOCK | Drug Manufacturers—General | NYE

Last Closing Price

USD 193.02

Change

0.00 (0.00)%

Market Cap

USD 63.66B

Volume

0.01B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

-0.19 (-0.13%)

USD378.74B 23.01 14.87
PFE Pfizer Inc

-0.07 (-0.19%)

USD203.44B 23.43 16.62
MRK Merck & Co., Inc

-0.08 (-0.10%)

USD202.76B 17.72 12.42
NVS Novartis AG

+0.88 (+1.00%)

USD201.06B 28.32 13.47
ABBV AbbVie Inc

+0.24 (+0.23%)

USD183.47B 21.73 16.83
BMY Bristol-Myers Squibb Company

-0.38 (-0.60%)

USD142.86B 93.81 11.93
LLY Eli Lilly and Company

-0.15 (-0.10%)

USD138.61B 23.85 18.85
GSK GlaxoSmithKline plc

+0.14 (+0.38%)

USD92.05B 11.05 14.30

ETFs Containing AGN

Symbol Name Weight Mer Price(Change) Market Cap
PBI Pitney Bowes Inc 0.00 % 0.00 %

-0.01 (-0.17%)

USD1.04B
IQQA:F iShares Euro Dividend UCI.. 0.00 % 0.40 %

-0.01 (-0.07%)

USD0.62B
ISPA:XETRA iShares STOXX Global Sele.. 0.00 % 0.46 %

-0.09 (-0.35%)

USD1.15B
IQQA:XETRA iShares Euro Dividend UCI.. 0.00 % 0.40 %

-0.04 (-0.25%)

USD0.62B
EXSH:XETRA iShares STOXX Europe Sele.. 0.00 % 0.31 %

-0.11 (-0.70%)

USD0.29B
EXSG:XETRA iShares EURO STOXX Select.. 0.00 % 0.31 %

-0.05 (-0.31%)

USD0.65B
EL4G:XETRA Deka EURO STOXX Select Di.. 0.00 % 0.30 %

-0.04 (-0.27%)

USD0.14B
C051:XETRA ComStage EURO STOXX Selec.. 0.00 % 0.25 %

-0.08 (-0.24%)

USD0.05B
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

-1.00 (-0.48%)

N/A
ISPA:F iShares STOXX Global Sele.. 0.00 % 0.46 %

-0.13 (-0.49%)

USD1.22B
EXSH:F iShares STOXX Europe Sele.. 0.00 % 0.31 %

-0.07 (-0.44%)

USD0.31B
IDVY:LSE iShares Euro Dividend UCI.. 0.00 % 0.40 %

-1.60 (-0.10%)

USD0.62B
EXSG:F iShares EURO STOXX Select.. 0.00 % 0.31 %

-0.01 (-0.08%)

USD0.69B
EL4G:F Deka EURO STOXX Select Di.. 0.00 % 0.30 %

N/A

USD0.16B
C051:F ComStage EURO STOXX Selec.. 0.00 % 0.25 %

-0.02 (-0.05%)

USD0.06B
SPMV:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-1.02 (-0.49%)

N/A
MVUS:PA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-0.73 (-0.30%)

N/A
IWVU:LSE iShares Edge MSCI World V.. 0.00 % 0.30 %

-0.03 (-0.70%)

USD1.91B
IWVL:LSE iShares Edge MSCI World V.. 0.00 % 0.30 %

-0.27 (-0.87%)

USD1.91B
IUVL:LSE iShares Edge MSCI USA Val.. 0.00 % 0.20 %

-0.05 (-0.72%)

USD1.07B
OSX2:XETRA Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

-1.30 (-0.63%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.97% N/A N/A N/A N/A
Dividend Return 0.77% N/A N/A N/A N/A
Total Return 1.74% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 4.12% N/A N/A N/A N/A
Dividend Return 0.80% N/A N/A N/A N/A
Total Return 4.92% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -39.64% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.64% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.25% N/A N/A N/A N/A
Dividend Return 1.27% N/A N/A N/A N/A
Total Return -4.98% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.22% N/A N/A N/A N/A
Risk Adjusted Return -22.41% N/A N/A N/A N/A
Market Capitalization 63.66B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.00 N/A N/A N/A N/A
Price/Book Ratio 1.10 N/A N/A N/A N/A
Price / Cash Flow Ratio 8.79 N/A N/A N/A N/A
EV/EBITDA 28.44 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -4.15% N/A N/A N/A N/A
Return on Invested Capital -0.19% N/A N/A N/A N/A
Return on Assets 0.74% N/A N/A N/A N/A
Debt to Equity Ratio 31.14% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.22 N/A N/A N/A N/A
Short Percent 4.56% N/A N/A N/A N/A
Beta 1.20 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike